Skye Bioscience (SKYE) earnings call transcripts

Management reframed the 200-mg monotherapy result as an exposure shortfall, positioning higher-dose testing and GLP-1 add-on use as the next proof points.

Management framed the call as evidence that combination activity validates the mechanism, while dose optimization and manufacturing readiness define the next decisions.

Management framed the call as a transition from disciplined execution to proof, with Phase 2a data imminent and a broader maintenance thesis emerging. Top-line Phase 2a results remain on track for late Q3, early Q4.

Management framed the quarter around early enrollment completion, a longer safety and efficacy window, and preclinical evidence supporting peripheral CB1 inhibition.

Management framed 2025 as a data year, highlighting faster enrollment, a longer treatment extension, and a differentiated safety thesis for peripheral CB1 inhibition.

Management framed the call around differentiating its CB1 antibody from brain-penetrant small molecules and executing the obesity trial toward 2025 data milestones.